STOCK TITAN

Arrowhead Pharma Stock Price, News & Analysis

ARWR Nasdaq

Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.

Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.

Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.

All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.

Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.

Rhea-AI Summary

Arrowhead Pharmaceuticals presented new clinical data on RNAi-based therapies ARO-APOC3, ARO-ANG3, and olpasiran at the AHA Scientific Sessions 2022. ARO-APOC3 showed significant decreases in triglycerides by 86% and increases in HDL-C by 99%. ARO-ANG3 reduced triglycerides by 59% and LDL-C by 32%, while olpasiran decreased lipoprotein(a) levels by over 95% in ASCVD patients. The company plans to discuss these findings and its future plans in a virtual event on November 9, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced on October 4, 2022, the approval of inducement grants for 39 new employees, totaling up to 117,500 restricted stock units. This includes 30,000 restricted stock units awarded to Peter Carignan, the new vice president of clinical operations. The grants, which fall under NASDAQ Listing Rules, are outside existing shareholder-approved equity incentive plans and will vest over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present interim clinical data on ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2022 in Chicago, from November 5-7, 2022. The SHASTA-2 and ARCHES-2 Phase 2 studies focus on patients with severe hypertriglyceridemia and mixed dyslipidemia, respectively. A virtual investor event is scheduled for November 9, 2022, to discuss these findings and future developments. Full data from ARCHES-2 is expected in the first half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences clinical trial
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will participate in several upcoming events in September 2022. Key presentations include:

  • ERS International Congress: September 4-6, 2022, by Erik Bush on MMP7 gene silencing.
  • Wells Fargo Healthcare Conference: September 7-9, 2022, investor meetings with Vincent Anzalone.
  • H.C. Wainwright Global Investment Conference: September 12-14, 2022, fireside chat by Christopher Anzalone.
  • Baird Global Healthcare Conference: September 13-14, 2022, also featuring Christopher Anzalone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application to commence a Phase 1/2a clinical trial for ARO-MMP7, an investigational RNA interference therapeutic targeting matrix metalloproteinase 7 (MMP7) for idiopathic pulmonary fibrosis (IPF). The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers and IPF patients. This initiative expands Arrowhead's clinical pipeline, which includes other lung disease candidates. The trial approval is pending from the local Ethics Committee and the New Zealand Medicines and Medical Devices Safety Authority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its fiscal Q3 results for the period ending June 30, 2022, revealing a revenue of $32.4 million, down from $45.9 million in Q3 2021. The operating loss increased to $72.9 million, compared to $31.9 million the previous year. Notably, the company published promising Phase 2 clinical results for fazirsiran, with 58% of patients showing fibrosis regression. Arrowhead also initiated clinical studies for ARO-MUC5AC and ARO-RAGE and expanded its team. Cash resources stand at $582.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days.

Arrowhead develops innovative RNAi-based therapeutics targeting intractable diseases through gene silencing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences earnings
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has approved inducement grants for 34 new employees on July 1, 2022. The grants comprise a total of 138,000 restricted stock units, with 70,000 units awarded to the new chief commercial officer, Tracie Oliver. These grants are outside the company's stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on developing RNA interference-based therapies to treat severe diseases by silencing problematic genes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in two Phase 1/2a clinical trials for ARO-MUC5AC and ARO-RAGE, innovative RNA interference therapeutics targeting mucin production and inflammatory responses in lung diseases. ARO-MUC5AC-1001 and ARO-RAGE-1001 trials aim to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and asthma patients. CEO Chris Anzalone highlighted this as a pivotal milestone in the company's mission to tackle difficult-to-drug targets in respiratory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.9%
Tags
Rhea-AI Summary

Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags

FAQ

What is the current stock price of Arrowhead Pharma (ARWR)?

The current stock price of Arrowhead Pharma (ARWR) is $16.79 as of July 3, 2025.

What is the market cap of Arrowhead Pharma (ARWR)?

The market cap of Arrowhead Pharma (ARWR) is approximately 2.2B.
Arrowhead Pharma

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

2.22B
120.11M
13.2%
74.66%
6.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA